Eric Hoffman, PhD.

Dr. Hoffman has worked on DMD since the late 1980’s, first working as a post-doctoral fellow with Louis Kunkel at Boston Children’s to identify the gene and protein (1986-1990), then running his own research group at University of Pittsburgh (1990-1998),

More >

John McCall, PhD.

Dr. McCall began his career as a medicinal chemist with Upjohn and subsequently held positions with Pharmacia and Upjohn, Pharmacia, and Pfizer. He was Director of CNS Research with Upjohn, Vice President and Global Head of Chemistry for both Pharmacia

More >

Jesse Damsker, PhD.

Dr. Damsker has an extensive background in immunology and the regulation of inflammatory diseases. He earned his doctorate in immunology at the George Washington University School of Medicine and completed a post-doctoral fellowship at the National Institutes of Health. In

More >

Johannes van den Anker, MD, PhD

Dr. van den Anker is a pediatric clinical pharmacologist and authority in pediatric and neonatal clinical drug trials. He is actively involved in pediatric clinical pharmacology programs in both the USA (Children’s National Medical Center, Washington, DC and Johns Hopkins

More >

Laura Hagerty, PhD

Dr. Hagerty has spent more than a decade pursuing therapies for muscular dystrophy. She began her career in drug development as a preclinical pharmacologist with Acceleron Pharma and later with the Skeletal Muscle Metabolism Discovery Unit at GlaxoSmithKline. Prior to joining

More >